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The US National Cancer Institute (NCI) estimates that
at least 13.7 million cancer survivors were alive in the
United States in 2012, and this number will approach
18 million by 2022.1
Modern oncologic treatments brought a strong reduction
in the mortality rate among patients with cancer.2 How-
ever, the antineoplastic-related cardiotoxicity (CTX) is a
major cause of morbidity and mortality in cancer survi-
vors.3
In a US National Health and Nutrition Examination
survey of 1807 cancer survivors followed for 7 years,
33% of survivors died of heart disease and 51% of cancer.1
In this review, we will discuss the management of cardio-
vascular side-effects of target therapy in oncology.
Foremost, it is necessary to know that any tyrosine
kinase inhibitor (TKI) has potential CTX, and while
cardiac events may or may not be likely, it is necessary
for clinicians to know what to do before, during, and after
treatment with these drugs.CTX from target therapy refers mostly to four groups
of drugs:(1) EAttrib
ged in
ardpidermal growth factor receptor 2 (HER2/ErbB2)
inhibitors.(2) Angiogenic inhibitors.
(3) Directed Abelson murine leukemia viral oncogene
homolog (ABL) inhibitors.
(4) Proteasome inhibitors.In addition to these, there are some miscellaneous agents
that we will discuss individually.
Target therapy
Target therapy blocks the growth of cancer cells by
interfering with specific targeted molecules needed for
cell proliferation, tumor growth, and systemic spread.4
Progress in therapy and the increase in number of
long-term survivors reveal the issue of cardiovascular
side-effects of target therapy.DOI:10.2459/JCM.0000000000000383
ution-NonCommercial-NoDerivatives 4.0 License, where it is permissible to
any way or used commercially.
iology. All rights reserved.
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Schematic representation of mechanisms of action of target therapy. Target therapy may affect tumor growth inhibiting specific enzymatic activities
(e.g. tyrosine kinase inhibitor and proteasome inhibitors), or binding specific receptors/ligands, thus inhibiting their biological functions (e.g.
monoclonal antibodies trastuzumab, pertuzumab, and bevacizumab).Target therapy may affect by ‘on-target’ or ‘off-target’
toxicities. On-target refers to excessive and adverse
pharmacologic effects at the target of interest, shared
by all agents that reliably inhibit a specific target.
Off-target refers to adverse effects as a result of modu-
lation of other targets.5 A schematic representation of the
mechanisms of action of principal drugs used in target
therapy are reported in Fig. 1.
Cardiovascular side-effects of target therapy have
become an important problem, for example, in patients
treated with ponatinib, a multitarget TKI that presents a
broad range of action, 11% developed arterial thrombosis
and at least 5% arrhythmia.6 Moreover, sunitinib, a TKI
of vascular endothelial growth factor, causes a high risk of
congestive heart failure, hypertension (HTN), myo-
cardial ischemia, and thromboembolism.7 Therefore,
we retain the important collaboration between cardiolo-
gist and oncologists to evaluate and monitor the patients
that receive target therapy at risk of CTX.
Prevention and diagnosis of cardiac adverse events
The Common Terminology Criteria for Adverse Events
developed by NCI, provides a system for the consistent
description and grading of cardiovascular adverse events© 2016 Italian Federation of Caobserved during clinical trials of therapeutic agents.8
The criteria for cardiovascular adverse events have been
revised and are shown in Table 1.8,9
Risk factors
A detailed clinical assessment is essential in identifying
individuals at risk for cardiovascular side-effects. Cardiac
evaluations of patients at particular risk for CTX should
be carried out in conjunction with the oncologist, so that
the choice of therapy may be optimized.
The patients should be evaluated for cardiovascular risk
before undergoing treatment with antineoplastic drugs.10
Depending on the patient-specific risk factors, patients
should be advised about lifestyle changes, and in some
cases, their drug regimen may have to be changed. It is
well known that physical exercise has a positive effect on
cardiovascular reserve, risk factors and total mortality,11
and b-blockers, angiotensin-converting enzyme (ACE)
inhibitors and Ca2þ antagonist are recommended for
initial HTN therapy. Statins are recommended to main-
tain low-density lipoprotein cholesterol levels at less than
100mg/ml. Antidiabetic therapy is recommended to
maintain glycosylated hemoglobin levels at less than
7%.12 In addition to the above described risk factors,rdiology. All rights reserved.
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Table 1 The National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE 4.03) grading severity of cardiac events
associated with tyrosine kinase inhibitors9
Cardiac event Grade 1 Grade 2 Grade 3 Grade 4 Grade 5
Hypertension Prehypertension Stage 1 hypertension – SBP
140–159 mmHg or DBP 90–
99 mmHg); medical
intervention indicated;
recurrent or persistent
(>24 h); symptomatic
increase by >20 mmHg
(DBP) or to>140/90 mmHg if
previously within normal limits;
monotherapy indicated
Stage 2 hypertension – SBP
>160 mmHg or DBP
>100 mmHg; medical
intervention indicated; more
than one drug or more
intensive therapy than
previously used indicated
Life-threatening consequences
(e.g. malignant hypertension,
transient or permanent
neurologic deficit,
hypertensive crisis); urgent
intervention indicated
Death
Heart failure Asymptomatic with
laboratory (e.g. brain
natriuretic peptide) or
cardiac imaging
abnormalities
Symptoms with mild-to-
moderate activity or exertion
Severe with symptoms at rest or
with minimal activity or
exertion; intervention
indicated
Life-threatening consequences;
urgent intervention indicated
(e.g. continuous intravenous
therapy or mechanical
hemodynamic support
Death
QT prolongation QTc 450–480 ms QTc 481–500 ms QTc >501 ms on at least two
separate electrocardiograms
QTc >501 ms or >60 ms
change from baseline and
torsades de pointes, or
polymorphic ventricular
tachycardia, or signs or
symptoms of serious
arrhythmia
-
QT is the duration of ventricular depolarization and repolarization. QTc, corrected QT interval.other factors that could contribute to cardiac stress
should not be ignored. Risk factors should be modified
or reduced by treating HTN, normalizing lipids, and
encouraging weight reduction and smoking cessation.
Imaging
CTX is generally evaluated by assessing the left ventri-
cular ejection fraction (LVEF). To date, the optimal
method is echocardiography and the frequency of cardiac
monitoring depends on the drug regimen. In the past,
multiple gate acquisition was used more frequently,
but this technique is now used only in select cases.
We recommend performing a baseline echocardiogram
before starting therapy with any drugs that have known
or potential CTX.
A 2010 study13 demonstrated that for serial monitoring of
ejection fraction in patients with breast cancer receiving
adjuvant trastuzumab after treatment with anthracy-
clines, real-time three-dimensional transthoracic echocar-
diography yields measurements comparable with those of
conventional multiple gate acquisition, using cardiac
magnetic resonance as the gold standard. Moreover,
noncontrast three-dimensional transthoracic echocardio-
graphy was the most reproducible technique for LVEF
and LV volume measurement over 1 year of follow-up in
patients undergoing cancer therapy.14
Diastolic indices lacked the predictive value for impaired
systolic function and the routine assessment of diastolic
flow characteristics does not offer additional infor-
mation.15 A reduction in systolic mitral annular motion,
as measured using tissue Doppler imaging, has been
noted as early as 3 months following therapy and can
predict the development of LV systolic dysfunction.16
However, other studies have not confirmed this finding17© 2016 Italian Federation of Cand no clear link between tissue Doppler imaging
diastolic abnormalities and systolic dysfunction has
been demonstrated.
Recent studies have shown that global longitudinal strain
(GLS) identifies LV dysfunction earlier than convention-
al echocardiographic measures in patients treated
with chemotherapy.
A meta-analysis study suggested that GLS might have
prognostic value for the development of CTX; however,
this was on the basis of results from eight studies with
fewer than 500 patients, most of which had only 1 year of
follow-up data. Moreover, the definition of CTX was
ambiguous, and the majority of patients had LVEF
within the normal range.18
Another study [St. James Lifetime Cohort (SJLIFE)
study] reported that the evaluation of GLS can provide
evidence of cardiac dysfunction in almost one in three
adult survivors with normal LVEF.19
These observation data are insufficient for justifying a
change of practice to use GLS for the surveillance of
these patients because the data are nonrandomized, and
there is no evidence that the identification of subclinical
dysfunction will change the outcomes of these patients.
However, Plana et al.20 propose the use of GLS in the
algorithms of treatment initiation for all drugs potentially
associated with LV dysfunction, and for the identification
of toxicity and the initiation of cardioprotection.
Regarding MRI, Fallah-Rad et al.16 emphasized another
important aspect of trastuzumab-related CTX. They
showed that in trastuzumab cardiomyopathy there is
evidence of subepicardial linear-delayed enhancement
of the LV lateral wall, with a progressive decline inardiology. All rights reserved.
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Table 2 The prevention, monitoring, and management of cardiac events in patients undergoing cytotoxic chemotherapy22,25
Treatment phase Patient profile Management strategy
Before trastuzumab-based therapy A. No cardiac history of risk factors with
normal EF
Treat and monitor EF every 3 months
B. Cardiac history and/or risk factors with
normal EF
Treat. Ask of symptoms and perform PE before each cycle
C. Decreased EF Treat low EF (ACE-I or ARB, BB) and remeasure
Individual decisions about initiating trastuzumab
During trastuzumab-based therapy First decrease in EF Trastuzumab holiday for 1 month
A. Treat HF and remeasure
1. Return to baseline. Restart trastuzumab
2. If EF remains low: intensify HF treatment and remeasure
3. If EF remains low: individual decisions
Second decrease in EF A. Stop trastuzumab
B. If trastuzumab only option: ‘holiday’ and maximize HF therapy
Completion of trastuzumab-based therapy No change in EF and no symptoms
during treatment
If you have already used anthracyclines is necessary to monitor
LVEF at the end of treatment and after 1.2 and 5 years if
doxorubicin <200 mg/m2. More strict monitoring if dosage
>200mg/m2. In the case of only trastuzumab, we advice,
anyway, follow-up, considering the last results of real-world
retrospective studies
EF decreased or symptoms of heart
failure during therapy with trastuzumab
Continue HF treatment. Monitor according to clinical practice for
HF. The duration of therapy for HF is variable, if previous
anthracyclines may be required for life
The management of cardiac dysfunction before trastuzumab, a major integration to Suter’s algorithm (modified from Carver25), is indicated in bold. The ejection fraction is
considered to be reduced when it declines according to Suter’s limits (EF<44, or EF 45–49 and >10 from baseline26). ACE-I, angiotensin-converting enzyme inhibitor;
ARB, angiotensin receptor blocker; BB, b-blocker; EF, ejection fraction; HF, heart failure; PE, physical examination.ejection fraction, despite the discontinuation of trastu-
zumab and the initiation of heart failure therapy.
However, other researchers have not confirmed these
data, and we believe that other diagnostic sequences,
such as MRI, should be evaluated in prospective studies.
MRI could be used in clinical practice to select cases or
when it is impossible to acquire good images with
echocardiography.
The management of epidermal growth factor receptor 2
inhibitor cardiotoxicity
Trastuzumab
Anti-ErbB2 CTX is represented mainly by LV systolic
dysfunction and heart failure.
The main antihuman ErbB2 agent is trastuzumab, a
humanized monoclonal antibody against the extracellular
domain of ErbB2. Trastuzumab treatment is an integral
part of standard treatments for breast cancer with
HER2 overexpression, and large-scale clinical studies
have shown that up to 7 or 28% of patients suffer from
cardiac dysfunction when trastuzumab is used in mono-
therapy, or in combination with anthracyclines plus
cyclophosphamide.21
Before starting trastuzumab treatment, a careful evalu-
ation of the patient’s medical history, baseline ejection
fraction, and correction of risk factors is needed.22
Patients treated with trastuzumab are at a higher risk of
developing cardiovascular complications, particularly if
they have a history with prior/concomitant anthra-
cyclines, aremore than 50 years old, have previous cardiac
disease (ejection fraction <55%), have a higher BMI,
HTN, and abnormal renal function. Such patients might© 2016 Italian Federation of Carequire interventions, such as cardioprotective agents
[e.g. ACE inhibitors, angiotensin receptor blockers
(ARBs), and b-blockers].3,23,24
Patients who are not eligible to start trastuzumab treat-
ment for low ejection fraction should begin ACE inhibi-
tors or ARB and b-blockers, and should be referred to
a cardiologist25,26 (Table 2). A repeated assessment of
cardiac function should occur every 3 months.
Upon initiating trastuzumab, if a patient’s ejection
fraction declines according to the Suter limits26 (ejection
fraction <44, or ejection fraction 45–49 and >10 from
baseline), trastuzumab should be continued for 4 weeks
and routine treatment for heart failure should be initiated.
The target dose of heart failure drugs should be achieved
by increasing the dose every 1–2 weeks while monitoring
renal function and electrolytes, weekly or every 2 weeks,
and trying to reach the target dose within 4 weeks. After
dose titration, the ejection fraction should be measured
and, if it returns tobaseline, heart failuremedication should
be continued, and trastuzumab can be restarted.12 The
ejection fraction values of most patients return to baseline
within 1–2 months. In the case of persistently low ejection
fraction values or in symptomatic patients, aldosterone
inhibitors, an ARB, and digoxin should be administered.12
If the ejection fraction values returns to normal, trastuzu-
mab treatment may be restarted. If the ejection fraction
values remain low, individual decisions are made based on
the patient’s clinical conditions and prognosis.
If the patient is receiving trastuzumab, and the ejection
fraction declines a second time while receiving stable
heart failure treatment, the permanent discontinuation of
trastuzumab is recommended.rdiology. All rights reserved.
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ejection fraction and no symptoms during treatment, if
the patient has already been treated with anthracyclines,
it is necessary to monitor the LVEF at the end of
treatment and after 1, 2, and 5 years, if the doxorubicin
dosage is less than 200mg/m2. Stricter monitoring is
necessary if the dosage is higher than 200mg/m2. In cases
of therapy with only trastuzumab, we advise follow-up in
consideration of the latest results from real-world retro-
spective studies.27,28
If after the end of trastuzumab therapy, the ejection
fraction is decreased or the patient has symptoms or heart
failure during therapy, it is necessary to continue heart
failure treatment and to monitor the patient according to
the guidelines for heart failure.29 The duration of therapy
for heart failure is variable, and if anthracyclines
were required previously, heart failure therapy may be
required for life.
In metastatic breast cancer, trastuzumab treatment has
imminent life-extending potential if clinicians use it
more aggressively with considerations that the benefits
of therapy may outweigh the risks of cardiac dysfunction.
According to the Carver25 protocol, patients with asymp-
tomatic heart failure may continue to receive trastuzu-
mab unless their ejection fraction has decreased more
than 20% or to less than 40%, or their ejection fraction is
less than 30%. In these cases, trastuzumab is adminis-
tered for at least one cycle and is titrated to the maximal-
tolerated doses of heart failure medical therapy, and the
ejection fraction value is remeasured. If the ejection
fraction improves to more than 44%, trastuzumab may
be resumed. In patients with symptomatic heart failure,
or ejection fraction values less than 30%, trastuzumab
should be discontinued permanently.
As we have already discussed in the imaging section, the
study of GLS by two-dimensional speckle tracking could
be an interesting approach in the identification of early
cardiac damage.
A reduction of GLSmore than 15% from baseline is likely
abnormal.30 The use of GLS could be an effective
parameter for identifying systolic dysfunction and
responses to cardioprotection.31
As oncologists know, the reduction and discontinuation of
treatment for only 1 month compromises the efficacy of
trastuzumab treatment.32 If randomized prospective stu-
dies will confirm the utility of reducing GLS to identify
early myocardial damage predictive of CTX, we could
use this technique in routine clinical practice to protect
the heart without affecting trastuzumab therapy.
Lapatinib, pertuzumab, and ado-trastuzumab emtansine
The CTX of the new ErbB2 inhibitors, ado-trastuzumab
emtansine, pertuzumab, and lapatinib, is not superior or
additive to that of trastuzumab alone.33–35 For this© 2016 Italian Federation of Creason, we advise similar management to that of trastu-
zumab, with consideration of the fact that these drugs are
used, at the moment, only in the metastatic settings.
The management of angiogenic inhibitor cardiotoxicity
The most important cardiovascular side-effects of the
angiogenesis inhibitors are HTN, coronary artery disease,
LV dysfunction/heart failure, QT prolongation, and
thrombosis.
Hypertension
The most common cardiovascular risk factor for cardiac
events with the angiogenic inhibitor therapy is HTN.
Other risk factors include: age (men >55 years and
women >65 years), hyperlipidemia, smoking, diabetes
mellitus, a family history of early heart disease
(men< 55 years and women <65 years), obesity, a
sedentary lifestyle, preexisting HTN, and the Hemolysis
Elevated Liver enzymes and Low Platelet count
(HELLP) syndrome.36 The HELLP syndrome is a var-
iant of preeclampsia. ‘HELLP’ is an abbreviation of the
three main features of the syndrome: hemolysis, elevated
liver enzymes, and a low platelet count. HELLP
syndrome occurs in 4–12% of patients with preeclampsia
or eclampsia and seems to be linked to the dysregulation
of VEGF signaling.
Therefore, the evaluation and treatment of HTN is a
practical starting point for interventions for CTX induced
by angiogenic inhibitors.37,38
The Cardiovascular Toxicities Panel of the NCI has
definedgrade1 toxicity aspre-HTN(SBP120–139mmHg
or DBP 80–89mmHg). Patients with pre-HTN should
begin antihypertensive therapy, which should eventually
be reinforced with other agents 3–7 days before starting
the angiogenic inhibitor therapy38–40 (Fig. 2).
During angiogenic inhibitor therapy, blood pressure (BP)
monitoring should be performed every week for the first
8 weeks and before each new infusion cycle. If the BP
stays less than 130/80mmHg, angiogenic inhibitor
therapy can be continued, but if BP increases to at least
140/90mmHg, it is necessary to reinforce the regimen
with antihypertensive drugs. In cases of hypertensive
crisis, it is necessary to stop angiogenic inhibitors and
administer antihypertensive drugs.Myocardial ischemia
The recommendations for the management of myo-
cardial ischemia include:(1) Cardardiology consultation in patients with asympto-
matic ECG changes and in those with symptoms
suggesting myocardial ischemia.(2) Suspending angiogenic inhibitor therapy in case of
documented myocardial ischemia. A collaborative
decision should then be made as to whether moreiology. All rights reserved.
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Fig. 2
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The management of hypertension induced by angiogenic inhibitors. AI, angiogenesis inhibitor; CCB, calcium channel blocker; HT, hypertension.
Modified from Ederhy et al.40advanced cardiac testing (e.g. stress testing and
coronary angiography) is needed and whether the
benefits of resuming therapy with aggressive suppor-
tive care outweigh the risks.(3) Myocardial infarction during antiangiogenic inhibitor
therapy could indicate the permanent discontinu-
ation of that therapy.40Left ventricular dysfunction and heart failure
In the case of asymptomatic LV dysfunction, angiogenic
inhibitors should be continued in cases of mild (ejection
fraction decrease >15%, with ejection fraction >50%) or
moderate (ejection fraction 50–40%) dysfunction, while
monitoring for HTN. Only in severe (ejection fraction
<40%) LV dysfunction and in symptomatic patients is it
recommended to stop anticancer therapy, discuss alterna-
tive drugs, and treat the LV dysfunction (Fig. 3).41
Antiangiogenic drugs should then be resumed upon
ejection fraction improvement and the normalization
of symptoms, but the issue of reversibility of LV© 2016 Italian Federation of Cadysfunction and the opportunity for readministering anti-
angiogenic inhibitors after improvement to the New York
Heart Association III–IV criteria remain unclear.42,43
QT interval prolongation
The QT interval recorded on an ECG reflects the total
duration of ventricular activation and recovery.44 Several
correction formulae have been developed to improve the
accuracy of QT measurement with corrected QT (QTc)
values.44–49
Bazett’s correction is frequently used in clinical practice
and in the medical literature. However, Bazett’s correc-
tion overcorrects in cases of elevated heart rates and
undercorrects in cases with heart rates below 60 beats/
min (bpm) and, hence, is not an ideal correction. Frider-
icia’s correction is more accurate than Bazett’s correction
in study participants with such altered heart rates. The
NCI classification of five grades of QT prolongation
associated with TKIs is presented in Table 1.rdiology. All rights reserved.
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Fig. 3
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Considerations for the management of left ventricular dysfunction and heart failure induced by antiangiogenic therapies.39–41 Modified from Ederhy
et al.40 and Suter and Ewer.41It is difficult to evaluate the risk of developing life-
threatening arrhythmias from QTc prolongation.50,51
There is no correlation between the prolonged QTc
interval and the incidence of torsades de pointes and
sudden death. Additionally, the risk of potentially fatal
ventricular tachycardia is small.50
There are several factors that can influence the pro-
longation of QT in cancer patients treated with angio-
genic inhibitors:(1) Drugs: vandetanib, sunitinib, pazopanib (a higher
incidence with vandetanib has been reported), and
vemurafenib.(2) Coexisting conditions (e.g. noncardiac: hypothyroid-
ism and congenital long QT, and cardiac: LV
dysfunction and cardiac ischemia).(3) Concomitant medications: antidepressants, antie-
metics, antibiotics, antipsychotics, antifungals, anti-
histamines, and methadone.(4) Cancer therapy-related factors: nausea and emesis,
diarrhea, diuresis, and poor oral intake can result in
dehydration/electrolyte imbalances with subsequent
hypokalemia, hypomagnesemia, hypocalcemia, renal
insufficiency, hepatic dysfunction, and poorly
controlled diabetes.For all of the above reasons, the following must be
optimized to improve patient care:© 2016 Italian Federation of C(1) Dardata collection, using the ‘tangent’ method for QT
measurement and the Fridericia formula for heart
rate correction.(2) The identification of risk factors associated with
the repletion of electrolyte disturbances, particularly
Kþ and Mg2þ, and of concomitant QT-prolonging
medications.(3) Cardiac monitoring, using practice guidelines for
high-risk biological therapy and referring to Food and
Drug Administration guidelines for specific agents.A general algorithm for QT monitoring during antineo-
plastic therapy is shown in Fig. 4, but the management
could be different for each drug. It depends on the drug-
specific pharmacokinetics and pharmacodynamics. Thus,
it is necessary to develop a specific algorithm for
each drug.
Vandetanib, sunitinib, and pazopanib can prolong the QT
interval, and torsades de pointes and sudden death have
been reported with these drugs.52–54 The highest inci-
dence of these abnormalities has been seen with vande-
tanib. The package leaflet indicates that vandetanib
should not be administered in patients with hypocalcemia,
hypokalemia, hypomagnesemia, or long QT syndrome.
ECGs should be obtained at baseline, at 2–4 weeks, and
8–12 weeks after starting treatment and every 3 months
thereafter.37iology. All rights reserved.
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Fig. 4
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It has been shown that angiogenesis inhibitors, such as
bevacizumab, sorafenib, and sunitinib, may cause arterial
and venous thromboembolism. In a systematic review,
Faraque et al.55 demonstrated that the risk of any grade
thrombotic or thromboembolic events was significantly
higher with these drugs.
The Bevacizumab Expanded Access trial and Bevacizu-
mab Regimens’ I Investigation of Treatment Effect
studies found an arterial thromboembolic event inci-
dence of 3.3%–6.1% in treated patients,56 especially as
myocardial infarctions or cerebrovascular damage.57–59
Venous thromboembolism events are otherwise not
correlated with bevacizumab treatment in the literature.
Choueiri et al.59 found an arterial thromboembolic event
incidence of 1.3–1.8% during both sunitinib and sorafenib
therapy. Moreover, 1% of patients treated with sunitinib
were reported to have venous thromboembolic events.60
However, antithrombotic and antithromboembolic thera-
pies remain difficult to manage in patients treated with
antiangiogenic agents. Elice and Rodeghiero61 suggest
the administration of venous or arterial thromboprophy-
laxis, particularly in patients at the highest risk for
thrombosis or for those treated with a combination of
surgery and chemotherapy.
The overall incidence of severe hemorrhagic events with
bevacizumab was 2.8% with higher risks seen in patients
with renal cell carcinoma, nonsmall cell lung cancer
(NSCLC), and colorectal cancer.62 Similarly, the inci-
dence of hemorrhage for sorafenib and sunitinib was
16.7%.63
Data regarding the value of aspirin prophylaxis for arterial
thromboembolic events for patients on bevacizumab are
conflicting. Scappaticci et al.64 reported that in both© 2016 Italian Federation of Cabevacizumab-treated and control patients, aspirin use
was associated with an 1.3-fold increase in grades
3 and 4 bleeding events. Instead, Tebbutt et al.65 reported
slightly more grade 3 and 4 bleeding events among
aspirin users on bevacizumab (3.7%) than controls (1.8%).
Abelson murine leukemia viral oncogene homolog
inhibitors
Ponatinib
Ponatinib is a multitarget TKI that inhibits ABL and
blocks angiogenesis by inhibiting the actions of VEGF
and other growth factors (e.g. platelet-derived growth
factor). Ponatinib received approval for treatment of a
variety of tumors, including renal cell carcinoma, hepa-
tocellular cancer, gastrointestinal stromal tumors
(GISTs), thyroid cancer, pancreatic neuroendocrine
tumors, soft tissue sarcomas, refractory chronic
myelogenous leukemia (CML), and refractory metastatic
colorectal cancer. Higher rates of arterial thromboembolic
events are reported with ponatinib. Among patients
receiving ponatinib therapy for refractory CML, 11%
developed arterial thrombosis of any grade; 8% had
serious arterial thrombosis.66 The risk of serious throm-
boembolic events may be higher. Approximately 24% of
patients in the phase 2 clinical trial and approximately
48% of patients in the phase 1 clinical trial experienced
serious adverse vascular events, including fatal and life-
threatening heart attack, stroke, loss of blood flow to the
extremities resulting in tissue death, and severe narrow-
ing of blood vessels in the extremities, heart, and brain,
requiring urgent surgical procedures to restore blood
flow.66
Given the high rate of thromboembolic events in
patients treated with ponatinib, clinicians should care-
fully consider whether the benefits of treatment are likely
to exceed the risks, particularly for patients with one or
more cardiac risk factor.66rdiology. All rights reserved.
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Imatinib, a small molecule inhibitor of the breakpoint
cluster region-ABL, tyrosine protein kinase kit, the
platelet-derived growth factor receptor, and the non-
receptor tyrosine kinase sarcoma (SRC) family of
TKIs, are used in the treatment of Philadelphia
chromosome-positive CML (PhþCML) and GISTs.
In an early report of patients treated for PhþCML,
imatinib was associated with the development of severe
heart failure,67 prompting the manufacturer to revise
the drug labeling to include warnings about possible
heart failure.
Laboratory studies indicate that adverse cardiac events
in patients receiving imatinib are likely mediated by
the inhibition of ABL.67,68
Despite the biologic rationale for potential CTX in
patients receiving imatinib, subsequent publications
indicate a low incidence of clinically significant heart
failure in CML clinical trial settings (no more than
1%-2%69); and an increased risk for heart failure or LV
dysfunction has not been observed in patients receiving
imatinib for the treatment of GIST.70–72
However, obtaining a baseline assessment of LVEF in all
patients receiving imatinib (particularly for GIST where
it is not even clear that there is a risk of CTX) is not
supported by compelling data. Nonetheless, patients
receiving imatinib should be monitored for signs and
symptoms of heart failure, and physicians should have
a low threshold for the formal assessment of LV
dysfunction.
Guidelines for the management of imatinib toxicity from
the National Comprehensive Cancer Network suggest
that only patients with cardiac disease or risk factors for
heart failure who are receiving imatinib need to be
monitored carefully and that any patient with signs or
symptoms consistent with heart failure should be
evaluated and treated.73
Dasatinib and nilotinib
Dasatinib and nilotinib are two second-generation
multitargeted TKIs that are used for the treatment of
PhþCML. Both dasatinib and nilotinib have been
associated with QT prolongation.44 Abnormalities in
potassium and magnesium levels must be corrected prior
to drug initiation; other drugs that may affect the QTc
interval should be avoided; caution should be used in
patients at risk for QT interval prolongation, and serial
ECGs should be performed.
Although a definite causal relationship has not been
established, dasatinib has also been associated with chest
pain, pericardial effusion, pulmonary HTN, ventricular
dysfunction, and heart failure.74 The US prescribing
information states that 1.6% of 258 patients taking
dasatinib developed cardiomyopathy, heart failure,© 2016 Italian Federation of Cdiastolic dysfunction, fatal myocardial infarction, and/or
LV dysfunction.75
Proteasome inhibitors
Bortezomib and carfilzomib are proteasome inhibitors
of the first and second generation, respectively. They
are used for the treatment of multiple myeloma.
In clinical trials of carfilzomib, new onset or worsening
of preexisting heart failure with decreased LV function or
myocardial ischemia has been reported in approximately
7% of patients, and deaths because of cardiac arrest have
occurred within 1 day of drug administration.76 In
addition, pulmonary arterial HTN has been reported
in 2% of patients treated with carfilzomib.
In a phase II trial of 266 patients treated with carfilzomib
monotherapy for relapsedmyeloma, 10 experienced heart
failure (3.8%), four (1.5%) had a cardiac arrest, and two
(0.8%) had a myocardial infarction during the study.77
The risk did not appear to be cumulative, at least through
12 cycles of therapy. However, the magnitude of the
attributable risk, risk factors, and the natural history,
including the reversibility of carfilzomib-related CTX,
remain incompletely characterized. The recommended
dose modification based on CTX is available in the US
prescription information.
CTX might represent a class effect, as heart failure
events (acute pulmonary edema, cardiac failure, and
cardiogenic shock) have also been described in patients
treated with bortezomib. However, causality remains
unclear. In a phase III trial comparing bortezomib versus
dexamethasone for relapsed myeloma, the incidence of
treatment-emergent cardiac disorders during treatment
with bortezomib or dexamethasone was 15 and 13%,
respectively; seven patients receiving bortezomib (2%)
and eight patients receiving dexamethasone (2%) devel-
oped heart failure during the study.78 Similarly to the
outcomes of carfilzomib therapy, cardiac dysfunction
does not appear to be cumulative in patients treated
with bortezomib.79
Abnormalities appear to be largely reversible with prompt
therapy cessation and the initiation of traditional heart
failure treatment.80
For these reasons, we recommend a baseline assessment
of the LVEF before starting proteasome inhibitors.
Miscellaneous agents
Crizotinib and ceritinib
Crizotinib and ceritinib are orally active inhibitors of the
anaplastic lymphoma kinase. They are both approved for
the treatment of advanced or metastatic NSCLC. Sinus
bradycardia is common in patients receiving these agents
and can be profound, although it is generally asympto-
matic and not associated with other events, such as other
arrhythmias.ardiology. All rights reserved.
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advanced NSCLC, bradycardia was reported in only
12 of 240 patients who were assessable for treatment-
related CTX, and all cases were mild (grade 1 or 2) in
severity.81(2) In another report of 42 patients receiving treatment
with crizotinib for advanced NSCLC, there was an
average bpm decrease of 26 among all patients; 69%
had at least one episode of sinus bradycardia (heart
rate <60 bpm).82 Profound sinus bradycardia (heart
rate <50 bpm) developed in 13 patients (31%). None
of the patients who developed bradycardia during
treatment was symptomatic or had ECG changes
such as QTc interval prolongation.In addition to bradycardia, QTc interval prolongation has
been observed with both drugs, although it is uncommon.
Three percentage of 255 patients treated with ceritinib
experienced a QTc interval increase over baseline of
60ms; in a larger population of 304 patients treated with
the drug, only one (<1%) developed a QTc interval of
more than 500ms.83 The US prescribing information for
crizotinib and ceritinib recommends avoiding both drugs
in patients with congenital long QT syndrome and
patients with heart failure, bradyarrhythmias, electrolyte
abnormalities, or those who are taking other medications
known to prolong the QTc interval, in addition to per-
forming periodic monitoring with ECGs and assessments
of the serum electrolyte levels. Treatment interruption
and dose reduction is advised if the QTc interval exceeds
more than 500ms during treatment, with permanent
discontinuation if it recurs or is accompanied by arrhyth-
mia, heart failure, hypotension, shock, syncope, or tor-
sades de pointes.
Practice is variable regarding cardiac monitoring during
therapy; however, some clinicians perform a baseline
ECG for patients starting crizotinib or ceritinib only if
they have a known history of heart failure or cardiac
arrhythmia issues, and perform ECGs during therapy if
bradycardia (symptomatic or not) develops or if the
patient is started on another drug with known QTc
prolongation side-effects.
Vemurafenib
Vemurafenib, an orally available inhibitor of some
mutated forms of homolog B of rapidly accelerated fibro-
sarcoma kinase (BRAF), is approved for the treatment of
metastatic melanoma with a V600E BRAF mutation.
Vemurafenib has been associated with the prolongation
of the QTc interval. Furthermore, ECG and electrolyte
monitoring are recommended before treatment and
after dose modification. For patients starting therapy
with vemurafenib, ECGs are recommended at day 15,
monthly during the first 3 months of treatment, and every
3 months thereafter, and more often as clinically indi-
cated. If the QTc interval exceeds 500ms, treatment© 2016 Italian Federation of Cashould be temporarily interrupted, and electrolyte
abnormalities should be evaluated and corrected.84
Trametinib
Trametinib is an orally active inhibitor of the mitogen-
activated protein kinase enzymes (MAPK1 andMAPK2),
and it is approved for the treatment of metastatic mel-
anoma with a specific BRAF mutation. In clinical trials of
trametinib in patients with metastatic melanoma, LV
dysfunction has been observed in up to 11% of treated
patients.85
The US prescribing information recommends the
following86:(1) Ardiossess LVEF before initiating therapy, 1 month after
treatment initiation, and at 2 to 3-month intervals
during treatment.(2) Withhold treatment if the absolute LVEF decreases
by 10% from the pretreatment values to less than the
institutional lower limit of normal.(3) Permanently discontinue trametinib for symptomatic
heart failure, any absolute decrease in LVEF of more
than 20% from baseline that is below the lower
institutional limit of normal, and persistent LVEF
reductions of at least 10% from baseline that does not
resolve within 4 weeks.Conclusion
Cancer patients receiving chemotherapy have an
increased risk of developing cardiovascular compli-
cations, and the risk is even greater if there is a known
history of heart disease. Anthracycline and anthracycline-
like agents and agent targeting the human ErbB2, such as
trastuzumab, are the most frequently known anticancer
agents associated with CTX.87
In addition to trastuzumab, a wide range of other bio-
logical agents has been associated with CTX. To date,
there are more than 600 TKIs in development for cancer
treatment. Each of these drugs is potentially cardiotoxic
through their ‘on-target’ or ‘off-target’ effects on cardiac
tyrosine kinase. Moreover, the specificity profile of these
drugs and the biology of most TKIs are usually not
known, and thus each new drug will have its own unpre-
dictable impact on the risk of CTX.
For all patients receiving potential cardiotoxic therapy,
primary prevention to reduce cardiovascular risk may be
achieved bymeasures ‘that rest on common sense.’83 The
management of preexisting comorbidities (HTN, LV
dysfunction, arrhythmias, and metabolic disorder) should
be optimized and a healthy lifestyle should be encour-
aged both before and after initiating cancer therapy.
In the absence of specific cardiacmonitoring guidelines for
potentially cardiotoxic agents, the evaluation andmonitor-
ing of LVEF must be considered. The toxicity profile,
patient, and disease characteristics should be consideredlogy. All rights reserved.
Target therapy and angiogenesis inhibitors Maurea et al. e103when making this decision. When starting an agent that
may cause orworsenHTN, serial BPmonitoring should be
performed and maintained during therapy with that
particular drug. A proposed algorithm regarding interven-
tions for treatment-related HTN is provided in Fig. 2.
Outcomes may be improved when cancer survivors who
have been treated with potentially cardiotoxic drugs are
referred to centers with expertise in long-term surveil-
lance and risk-based medical care. Secondary prevention
of CTX after treatment currently depends on clinical
observations as research continues to identify reliable
measures of subclinical disease.
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